Oxford University researchers launched Phase 1 clinical trials for the world’s first Bundibugyo ebolavirus vaccine on July 13, 2026.
The experimental shot, designated ChAdOx1 BDBV, represents the first specific countermeasure developed against a filovirus that has driven the third-largest Ebola outbreak on record. As infections surpass 2,000 cases with around 1,000 deaths and a fatality rate of nearly 40% in the Democratic Republic of the Congo, international researchers and manufacturers are racing to establish clinical safety and build emergency stockpiles.
Rapid Development and Vaccine Platform Design
According to the University of Oxford, the vaccine candidate adapts the ChAdOx1 viral vector platform. This platform previously underpinned the Oxford-AstraZeneca Covid vaccine.
The vaccine uses the same viral vector technology as the Oxford/AstraZeneca COVID-19 vaccine but has been redesigned to target a protein found in the Bundibugyo virus. This approach trains the human immune system to recognize and respond quickly if a person is exposed to the virus.
Trial Structure and Manufacturing Stockpiles
The initial Phase 1 clinical study is taking place in Oxford, United Kingdom, enrolling 50 healthy adult volunteers aged 18 to 55. The trial evaluates the vaccine’s safety, tolerability, and immunogenicity.
To prepare for potential emergency deployments and larger-scale evaluations, the Serum Institute of India has already manufactured and stockpiled approximately 620,000 doses of the vaccine candidate. If the current UK trial confirms safety and strong immune responses, the vaccine will move into larger studies to determine the optimal dose, monitor for rare side effects, and confirm its effectiveness in preventing Bundibugyo Ebola during future outbreaks.
Cross-Reactive Potential of Existing Ebola Vaccines
While the Oxford trial marks the first test of a pathogen-specific vaccine, separate research published in the New England Journal of Medicine suggests that currently licensed Zaire Ebola vaccines may offer partial cross-reactive immunity. Investigators analyzed serum samples from 179 individuals vaccinated with existing formulations and detected antibody responses against the Bundibugyo strain at 28 days and three months post-vaccination.
The data showed that single-dose Ervebo, manufactured by Merck, and the two-dose heterologous regimen from a subsidiary of Johnson & Johnson both elicited measurable, though lower, antibody levels against Bundibugyo compared to their target Zaire strain. Commenting on these findings, Boghuma K. Titanji, MD, DTM&H, PhD, argued via social media that public health bodies should weigh intervention options carefully.
Titanji noted that decision-makers frequently face infectious disease emergencies without perfect evidence, balancing clinical uncertainty against the real costs of delay.
Parallel Therapeutics and Broad Global Response
Beyond preventive vaccines, health authorities are advancing therapeutic candidates to treat patients already infected with the Bundibugyo virus. The World Health Organization confirmed that clinical trials evaluating antiviral treatments, including remdesivir and the monoclonal antibody cocktail MBP134, are underway in the Democratic Republic of the Congo. These trials involve partnerships between the WHO, the DRC’s National Institute of Biomedical Research, and international medical organizations.
Other institutions are also pursuing strain-specific countermeasures. The Gamaleya Centre announced it is conducting preclinical laboratory tests on a dedicated Bundibugyo vaccine candidate designed from published genetic sequences. Meanwhile, developers such as the International AIDS Vaccine Initiative and Moderna are advancing distinct vector and mRNA platforms.
Whether cross-reactive antibody levels will translate into meaningful clinical protection remains the central question facing epidemiologists as the current epidemic continues to expand.
Related reading
